Ukimura Osamu, Marien Arnaud, Palmer Suzanne, Villers Arnauld, Aron Manju, de Castro Abreu Andre Luis, Leslie Scott, Shoji Sunao, Matsugasumi Toru, Gross Mitchell, Dasgupta Prokar, Gill Inderbir S
USC Institute of Urology, Keck School of Medicine, University of Southern California, 1441 Eastlake Ave, Suite 7416, Los Angeles, CA, 90089, USA.
Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA, 90089, USA.
World J Urol. 2015 Nov;33(11):1669-76. doi: 10.1007/s00345-015-1501-z. Epub 2015 Feb 6.
To compare the diagnostic yield of targeted prostate biopsy using image-fusion of multi-parametric magnetic resonance (mp-MR) with real-time trans-rectal ultrasound (TRUS) for clinically significant lesions that are suspicious only on mp-MR versus lesions that are suspicious on both mp-MR and TRUS.
Pre-biopsy MRI and TRUS were each scaled on a 3-point score: highly suspicious, likely, and unlikely for clinically significant cancer (sPCa). Using an MR-TRUS elastic image-fusion system (Koelis), a 127 consecutive patients with a suspicious clinically significant index lesion on pre-biopsy mp-MR underwent systematic biopsies and MR/US-fusion targeted biopsies (01/2010-09/2013). Biopsy histological outcomes were retrospectively compared with MR suspicion level and TRUS-visibility of the MR-suspicious lesion. sPCa was defined as biopsy Gleason score ≥7 and/or maximum cancer core length ≥5 mm.
Targeted biopsies outperformed systematic biopsies in overall cancer detection rate (61 vs. 41 %; p = 0.007), sPCa detection rate (43 vs. 23 %; p = 0.0013), cancer core length (7.5 vs. 3.9 mm; p = 0.0002), and cancer rate per core (56 vs. 12 %; p < 0.0001), respectively. Highly suspicious lesions on mp-MR correlated with higher positive biopsy rate (p < 0.0001), higher Gleason score (p = 0.018), and greater cancer core length (p < 0.0001). Highly suspicious lesions on TRUS in corresponding to MR-suspicious lesion had a higher biopsy yield (p < 0.0001) and higher sPCa detection rate (p < 0.0001). Since majority of MR-suspicious lesions were also suspicious on TRUS, TRUS-visibility allowed selection of the specific MR-visible lesion which should be targeted from among the multiple TRUS suspicious lesions in each prostate.
MR-TRUS fusion-image-guided biopsies outperformed systematic biopsies. TRUS-visibility of a MR-suspicious lesion facilitates image-guided biopsies, resulting in higher detection of significant cancer.
比较使用多参数磁共振(mp-MR)与实时经直肠超声(TRUS)图像融合的靶向前列腺活检对仅在mp-MR上可疑的临床显著病变与在mp-MR和TRUS上均可疑的病变的诊断率。
活检前的MRI和TRUS均采用3分制评分:高度可疑、可能和不太可能为临床显著癌症(sPCa)。使用MR-TRUS弹性图像融合系统(Koelis),对127例在活检前mp-MR上有可疑临床显著指标病变的连续患者进行系统活检和MR/US融合靶向活检(2010年1月至2013年9月)。将活检组织学结果与MR可疑程度和MR可疑病变的TRUS可见性进行回顾性比较。sPCa定义为活检Gleason评分≥7和/或最大癌芯长度≥5mm。
靶向活检在总体癌症检出率(61%对41%;p = 0.007)、sPCa检出率(43%对23%;p = 0.0013)、癌芯长度(7.5mm对3.9mm;p = 0.0002)和每芯癌症发生率(56%对12%;p < 0.0001)方面均优于系统活检。mp-MR上高度可疑病变与更高的活检阳性率(p < 0.0001)、更高的Gleason评分(p = 0.018)和更大的癌芯长度(p < 0.0001)相关。与MR可疑病变对应的TRUS上高度可疑病变具有更高的活检阳性率(p < 0.0001)和更高的sPCa检出率(p < 0.0001)。由于大多数MR可疑病变在TRUS上也可疑,TRUS可见性允许从每个前列腺的多个TRUS可疑病变中选择应靶向的特定MR可见病变。
MR-TRUS融合图像引导活检优于系统活检。MR可疑病变的TRUS可见性有助于图像引导活检,从而提高显著癌症的检出率。